Immvira nets $58m Series B
Immvira Group Company, a Chinese developer of new generation oncolytic viruses as potential cancer therapeutics, has raised $58 million in Series B financing.
16 June 2020•1 min read
Immvira Group Company, a Chinese developer of new generation oncolytic viruses as potential cancer therapeutics, has raised $58 million in Series B financing.
San Joaquin County to slow venture commitments
15 October 2026 · 2 mins read
DOWNLOAD: Fundraising holds steady in Q3
14 October 2026 · 2 mins read
Why Endeavor Catalyst is betting big on Southeast Asia
8 October 2026 · 4 mins read
Dig's new fund bets on infrastructure built around foundation models
6 October 2026 · 4 mins read
Meet venture capital’s 2026 Women of Influence
5 October 2026 · 4 mins read
Eyeing opportunities and how the Women of Influence see trends developing
5 October 2026 · 3 mins read
Pulse Fund backer impressed with founder's 'relentless' dedication to climate
30 September 2026 · 5 mins read
